Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RPRX Stock Forecast 2025-2026
$33.16
Current Price
$19.04B
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RPRX Price Targets
+41.8%
To High Target of $47.00
+26.7%
To Median Target of $42.00
-2.9%
To Low Target of $32.19
RPRX Price Momentum
+0.8%
1 Week Change
+3.8%
1 Month Change
+18.0%
1 Year Change
+29.9%
Year-to-Date Change
-3.1%
From 52W High of $34.20
+37.9%
From 52W Low of $24.05
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Royalty Pharma (RPRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RPRX and similar high-potential opportunities.
Latest RPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, RPRX has a bullish consensus with a median price target of $42.00 (ranging from $32.19 to $47.00). Currently trading at $33.16, the median forecast implies a 26.7% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPRX Analyst Ratings
5
Buy
2
Hold
0
Sell
RPRX Price Target Range
Low
$32.19
Average
$42.00
High
$47.00
Current: $33.16
Latest RPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 25, 2024 | Citigroup | Andrew Baum | Buy | Maintains | $40.00 |
| Aug 14, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $51.00 |
| Jul 11, 2024 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $51.00 |
| Jun 3, 2024 | UBS | Ashwani Verma | Neutral | Downgrade | $28.00 |
| Apr 12, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $38.00 |
| Feb 20, 2024 | JP Morgan | Chris Schott | Overweight | Maintains | $42.00 |
| Feb 20, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $50.00 |
| Nov 9, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $57.00 |
| Oct 11, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Aug 9, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $53.00 |
| Jul 11, 2023 | Morgan Stanley | Terence Flynn | Overweight | Reiterates | $52.00 |
| May 10, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $52.00 |
| Apr 10, 2023 | Tigress Financial | Buy | Reiterates | $0.00 | |
| Apr 10, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $50.00 |
| Apr 6, 2023 | Tigress Financial | Ivan Feinseth | Buy | Reiterates | $60.00 |
| Feb 16, 2023 | UBS | Ashwani Verma | Buy | Maintains | $48.00 |
| Dec 6, 2022 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $51.00 |
| Nov 9, 2022 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Oct 18, 2022 | JP Morgan | Chris Schott | Overweight | Maintains | $52.00 |
| Sep 13, 2022 | Scotiabank | Outperform | Initiates | $0.00 |
Royalty Pharma plc (RPRX) Competitors
The following stocks are similar to Royalty Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Royalty Pharma plc (RPRX) Financial Data
Royalty Pharma plc has a market capitalization of $19.04B with a P/E ratio of 17.4x. The company generates $2.26B in trailing twelve-month revenue with a 37.9% profit margin.
Revenue growth is -0.4% quarter-over-quarter, while maintaining an operating margin of +60.9% and return on equity of +13.0%.
Valuation Metrics
Market Cap
$19.04B
Enterprise Value
$24.36B
P/E Ratio
17.4x
PEG Ratio
7.6x
Price/Sales
8.4x
Growth & Margins
Revenue Growth (YoY)
-0.4%
Gross Margin
N/A
Operating Margin
+60.9%
Net Margin
+37.9%
EPS Growth
-57.9%
Financial Health
Cash/Price Ratio
+6.9%
Current Ratio
1.4x
Debt/Equity
73.6x
ROE
+13.0%
ROA
+4.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Royalty Pharma plc (RPRX) Business Model
About Royalty Pharma plc
What They Do
Acquires biopharmaceutical royalties for funding.
Business Model
The company makes money by purchasing royalties from drug developers, providing them with immediate capital for research and development. This model not only supports innovation in the pharmaceutical sector but also generates revenue through the royalties from successful therapies.
Additional Information
Royalty Pharma has a diversified portfolio across various therapeutic areas including oncology, neurology, and rare diseases, which mitigates operational risks while enhancing its economic potential. The company's sustainable financing model plays a crucial role in the healthcare market, fostering advancements and ensuring returns for investors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Pablo Gerardo Legorreta
Country
United States
IPO Year
2020
Website
www.royaltypharma.comRoyalty Pharma plc (RPRX) Latest News & Analysis
Latest News
Quick Summary
Royalty Pharma plc (NASDAQ:RPRX) will host its Q1 2025 Earnings Conference Call on May 8, 2025, at 8:30 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters
The earnings call provides insights into Royalty Pharma's financial health and strategic direction, influencing stock performance and investor sentiment. Key analysts' participation highlights market interest.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma plc (Nasdaq: RPRX) announced its Q1 2025 financial results and raised its full-year guidance for Portfolio Receipts.
Why It Matters
Royalty Pharma's Q1 results and raised guidance signal strong financial health and growth prospects, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma's Q1 2025 results show performance metrics that should be compared to Wall Street estimates and previous year's figures for a comprehensive analysis.
Why It Matters
Royalty Pharma's financial performance relative to estimates and previous years indicates growth potential or risk, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma (RPRX) reported Q3 earnings of $1.06 per share, surpassing the Zacks Consensus Estimate of $0.99 and up from $0.98 per share year-over-year.
Why It Matters
Royalty Pharma's earnings beat expectations, indicating strong financial performance and potential for growth, which can boost investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics
6 days ago
Quick Summary
Royalty Pharma (RPRX) is expected to report its quarterly performance metrics for March 2025, providing insights beyond standard Wall Street estimates.
Why It Matters
Analyzing Royalty Pharma's key metrics offers insights into its future performance, potentially influencing stock valuations and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10 days ago
Quick Summary
Royalty Pharma (RPRX) is not expected to meet key criteria for a potential earnings beat in its upcoming report, according to recent analysis.
Why It Matters
Royalty Pharma's potential inability to meet earnings expectations may signal weaker financial performance, impacting stock valuation and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About RPRX Stock
What is Royalty Pharma plc's (RPRX) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Royalty Pharma plc (RPRX) has a median price target of $42.00. The highest price target is $47.00 and the lowest is $32.19.
Is RPRX stock a good investment in 2025?
According to current analyst ratings, RPRX has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPRX stock?
Wall Street analysts predict RPRX stock could reach $42.00 in the next 12 months. This represents a 26.7% increase from the current price of $33.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Royalty Pharma plc's business model?
The company makes money by purchasing royalties from drug developers, providing them with immediate capital for research and development. This model not only supports innovation in the pharmaceutical sector but also generates revenue through the royalties from successful therapies.
What is the highest forecasted price for RPRX Royalty Pharma plc?
The highest price target for RPRX is $47.00 from at , which represents a 41.8% increase from the current price of $33.16.
What is the lowest forecasted price for RPRX Royalty Pharma plc?
The lowest price target for RPRX is $32.19 from at , which represents a -2.9% decrease from the current price of $33.16.
What is the overall RPRX consensus from analysts for Royalty Pharma plc?
The overall analyst consensus for RPRX is bullish. Out of 9 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $42.00.
How accurate are RPRX stock price projections?
Stock price projections, including those for Royalty Pharma plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 5:17 PM UTC